Hermetica Superfood Encyclopedia
The Short Answer
EPA and DHA are long-chain omega-3 polyunsaturated fatty acids that incorporate into phospholipid cell membranes, modulate NF-κB signaling, and serve as precursors to pro-resolving mediators (resolvins, protectins) that actively suppress chronic inflammation and support cardiovascular and neurological function. Large-scale randomized trials such as REDUCE-IT demonstrated that high-dose icosapentaenoic acid (4 g/day as ethyl ester) reduced major adverse cardiovascular events by 25% (HR 0.75; 95% CI 0.68–0.83; p<0.001) in patients with elevated triglycerides on statin therapy.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordomega-3 fish oil benefits
Omega-3 Fatty Acids (DHA/EPA) — botanical close-up
Health Benefits
**Triglyceride Reduction**
EPA and DHA dose-dependently lower serum triglycerides by 15–30% at 2–4 g/day by reducing hepatic VLDL synthesis and increasing lipoprotein lipase-mediated clearance, an effect recognized in FDA-approved prescription formulations.
**Cardiovascular Event Risk Reduction**
EPA/DHA reduce platelet aggregation, improve endothelial function via enhanced nitric oxide bioavailability, and lower atherosclerotic plaque vulnerability; high-dose EPA (4 g/day) cut major cardiovascular events by 25% in the REDUCE-IT trial among high-risk patients.
**Anti-Inflammatory Action**
DHA and EPA serve as substrates for enzymatic synthesis of resolvins (e.g., RvE1, RvD1) and protectins (e.g., PD1), bioactive lipid mediators that inhibit pro-inflammatory cytokines TNF-α and IL-6 and promote macrophage efferocytosis, actively resolving—rather than merely suppressing—inflammation.
**Neurological and Cognitive Support**
DHA preferentially accumulates in neuronal phospholipid membranes of the cerebral cortex and retina, supporting synaptic plasticity and neurogenesis through PPARγ and GPR120 receptor activation; adequate DHA status is associated with reduced risk of age-related cognitive decline and is essential for fetal brain development.
**Blood Pressure Modulation**
Regular consumption of 3 g/day combined EPA+DHA produces modest but clinically meaningful reductions in systolic blood pressure (approximately 2–4 mmHg) in hypertensive individuals through enhanced endothelial nitric oxide synthase (eNOS) activity and reduced thromboxane A2-mediated vasoconstriction.
**Mood and Mental Health**
Epidemiological and interventional data suggest EPA-predominant formulations (EPA:DHA ≥2:1) may reduce depressive symptom scores (Hamilton Depression Rating Scale reductions of ~2–4 points vs. placebo) by modulating serotonergic and dopaminergic neurotransmission and reducing neuroinflammatory cytokine burden.
**Joint and Systemic Inflammation**
In rheumatoid arthritis populations, supplementation with 2.7–3 g/day EPA+DHA over 12–24 weeks has been shown to reduce tender joint counts, morning stiffness duration, and NSAID requirement, consistent with competitive inhibition of arachidonic acid-derived pro-inflammatory eicosanoids (PGE2, LTB4).
Origin & History
Natural habitat
EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long-chain omega-3 polyunsaturated fatty acids concentrated in the fatty tissues of cold-water pelagic fish, particularly sardines (Sardinella lemuru) and anchovies (Engraulis encrasicholus) harvested from cold, nutrient-rich ocean waters off Chile, Peru, and the Black Sea. These small schooling fish accumulate omega-3s by consuming phytoplankton and zooplankton, the primary marine synthesizers of EPA and DHA. Commercial fish oil is extracted from whole fish or visceral side streams via mechanical pressing or solvent extraction, followed by molecular distillation to purify and concentrate EPA and DHA while removing heavy metals, PCBs, and dioxins.
“Sardines and anchovies have constituted essential dietary staples in Mediterranean, Iberian, and Pacific coastal cultures for millennia, with archaeological evidence of large-scale anchovy processing in ancient Roman garum (fermented fish sauce) production dating to at least 200 BCE, and sardine preservation in olive oil documented throughout the Phoenician and Greek trading networks. These small pelagic fish were historically consumed whole—including organs rich in fat-soluble nutrients—providing concentrated dietary omega-3s without the conceptual framework of isolated fatty acids. In traditional Japanese and Inuit dietary patterns, extraordinarily high consumption of cold-water oily fish has long been epidemiologically associated with low rates of cardiovascular disease, observations that catalyzed Bang and Dyerberg's landmark investigations into omega-3 biochemistry in Greenlandic Inuit populations during the 1970s, sparking modern fish oil research. The formal isolation and characterization of EPA and DHA as distinct bioactive compounds occurred in the late 1970s–1980s, transitioning these nutrients from cultural food traditions into one of the most commercially and clinically significant nutritional supplement categories globally.”Traditional Medicine
Scientific Research
Omega-3 fatty acids EPA and DHA represent one of the most extensively studied nutritional interventions, with thousands of peer-reviewed publications spanning in vitro, animal, and human clinical trial designs. The REDUCE-IT trial (n=8,179; multicenter RCT) demonstrated that icosapentaenoic acid ethyl ester (Vascepa) at 4 g/day reduced the primary composite cardiovascular endpoint by 25% (HR 0.75; 95% CI 0.68–0.83; p<0.001) over a median 4.9 years in statin-treated patients with elevated triglycerides. The STRENGTH trial (n=13,078) using a carboxylic acid EPA+DHA formulation at 4 g/day found no significant cardiovascular benefit versus corn oil, highlighting that formulation and EPA:DHA ratio meaningfully affect outcomes. Multiple Cochrane systematic reviews and meta-analyses (e.g., Abdelhamid et al., 2018, reviewing 79 RCTs with >112,000 participants) confirm reliable triglyceride reduction (−15 to −30%) and modest blood pressure effects, while cardiovascular mortality benefits remain formulation- and dose-dependent; the overall evidence base is considered strong for lipid outcomes and moderate-to-strong for cardiovascular event reduction at pharmacological doses.
Preparation & Dosage
Traditional preparation
**Triglyceride-form liquid oil**
000 mg combined EPA+DHA daily; natural triglyceride form from wild-caught sardine/anchovy offers ~70% greater bioavailability than ethyl ester form when taken with a fatty meal
1,000–3,.
**Re-esterified triglyceride (rTG) capsules**
000 mg EPA+DHA per day for general cardiovascular and anti-inflammatory support; considered the gold standard for absorption among supplement forms
1,000–2,.
**Ethyl ester capsules (EE form)**
2–4 g/day for triglyceride reduction and cardiovascular risk; bioavailability enhanced significantly when consumed with a high-fat meal
Widely used in clinical trials (e.g., Lovaza, Vascepa); effective at .
**Prescription-grade EPA-only (icosapentaenoic acid)**
4 g/day (2 × 2 g capsules with meals) as studied in REDUCE-IT; FDA-approved for severe hypertriglyceridemia (≥500 mg/dL) and cardiovascular risk reduction
**Standardized concentrates**
000 mg capsule delivers ~160 mg EPA + 110 mg DHA
Commercial sardine/anchovy-derived supplements standardized to minimum 33% total omega-3s (16% EPA, 11% DHA); a typical 1,.
**Timing**
Take with the largest meal of the day to maximize fat-soluble absorption and reduce gastrointestinal side effects (fishy burping); splitting doses twice daily further minimizes GI discomfort.
**Traditional dietary form**
000 mg EPA+DHA per serving; recommended as first-line by the American Heart Association
Two servings per week of oily fish (sardines, anchovies, mackerel) providing ~500–1,.
Nutritional Profile
Fish oil derived from sardines and anchovies is composed predominantly of triglycerides (~98% lipid content) with EPA (eicosapentaenoic acid, C20:5n-3) typically at 10–17% of total fatty acids and DHA (docosahexaenoic acid, C22:6n-3) at 11–21%, with DHA:EPA ratios ranging from 1.95:1 (anchovy) to 4.70–8.67:1 (Sardinella lemuru); total omega-3 content in commercial concentrates reaches 33–65% of total fatty acids. Minor but nutritionally relevant components include omega-6 arachidonic acid (<2%), oleic acid (C18:1n-9, ~8–12%), and naturally occurring fat-soluble vitamins A and D3 in non-refined fish liver fractions. Sardine and anchovy oils also contain trace amounts of CoQ10, astaxanthin (a carotenoid antioxidant that may retard oil oxidation), and naturally occurring phospholipids in whole-fish preparations. Bioavailability is significantly influenced by molecular form: re-esterified triglycerides > natural triglycerides > free fatty acids > ethyl esters in fasted state; co-administration with dietary fat increases absorption of ethyl ester forms by up to 300%.
How It Works
Mechanism of Action
EPA and DHA are incorporated into plasma membrane phospholipids—displacing arachidonic acid (AA)—which reduces the substrate availability for cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) enzymes, thereby lowering production of pro-inflammatory prostaglandins (PGE2), thromboxanes (TXA2), and leukotrienes (LTB4) while favoring synthesis of the less potent 3-series prostaglandins and 5-series leukotrienes. Both EPA and DHA antagonize NF-κB nuclear translocation—a master transcription factor controlling pro-inflammatory gene expression—and activate PPARα and PPARγ nuclear receptors, which upregulate anti-inflammatory and lipid oxidation gene programs. EPA serves as the primary precursor for E-series resolvins (RvE1, RvE2) and DHA for D-series resolvins (RvD1–RvD6) and protectins (PD1/neuroprotectin D1), specialized pro-resolving mediators (SPMs) that bind ChemR23 and GPR32 receptors to actively terminate inflammatory cascades and promote tissue homeostasis. DHA additionally activates GPR120 (free fatty acid receptor 4) on macrophages and adipocytes, suppressing TLR4-mediated inflammatory signaling and improving insulin receptor sensitivity, while enhancing endothelial nitric oxide synthase (eNOS) phosphorylation to promote vasodilation.
Clinical Evidence
The most pivotal trial, REDUCE-IT (2018), enrolled 8,179 high-risk cardiovascular patients already on statins with fasting triglycerides 135–499 mg/dL and demonstrated that purified EPA ethyl ester at 4 g/day reduced the five-point MACE composite (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, unstable angina) by a relative 25% and absolute 4.8% over ~5 years (NNT≈21). For triglyceride-lowering, meta-analyses consistently demonstrate 15–30% reductions with 2–4 g/day combined EPA+DHA across diverse populations, with a dose-response relationship well established. In rheumatoid arthritis RCTs, 12–24 weeks of 2.7–3 g/day EPA+DHA significantly reduced tender joint counts and NSAID use compared to placebo (SMD approximately −0.3 to −0.5). Evidence for neuropsychiatric indications (depression, cognitive decline prevention) is promising but more heterogeneous, with meta-analyses of EPA-dominant formulations showing statistically significant but modest antidepressant effects (Hedges' g ≈ 0.40–0.50), warranting cautious clinical interpretation.
Safety & Interactions
At standard supplemental doses of 1,000–3,000 mg EPA+DHA daily, fish oil from purified sardine and anchovy sources is well-tolerated; the most common adverse effects are mild and dose-dependent gastrointestinal symptoms including fishy aftertaste, eructation (burping), loose stools, and nausea, which can be minimized by enteric-coated capsules, freezing capsules before ingestion, or splitting doses with meals. High-quality third-party tested products (e.g., IFOS-certified, NSF-verified) demonstrate contaminant levels well below established safety thresholds for mercury, PCBs, and dioxins, making purified sardine/anchovy oil among the safest marine lipid sources. Clinically important drug interaction: omega-3s exhibit antiplatelet and mild anticoagulant activity; at doses ≥3 g/day, concurrent use with warfarin, clopidogrel, aspirin, or other anticoagulants/antiplatelets may augment bleeding risk, and INR monitoring is recommended—though the interaction is generally manageable and rarely clinically significant at standard doses. Contraindications include confirmed fish or seafood allergy; caution is advised in patients with implanted defibrillators (high-dose EPA+DHA may affect arrhythmia thresholds in specific populations), those scheduled for surgery (discontinue 7–10 days prior), and during pregnancy and lactation (2–3 g/day EPA+DHA is considered safe and beneficial, particularly for fetal neurodevelopment, but doses above 3 g/day should be discussed with a physician; avoid fish liver oil-based sources due to excess vitamin A).
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Eicosapentaenoic acid (EPA, C20:5n-3)Docosahexaenoic acid (DHA, C22:6n-3)Marine omega-3 fatty acidsN-3 long-chain polyunsaturated fatty acids (LC-PUFAs)Fish oilSardinella lemuru oilEngraulis encrasicholus oil
Frequently Asked Questions
How much EPA and DHA do I need daily for heart health?
For general cardiovascular health, the American Heart Association recommends at least 500–1,000 mg combined EPA+DHA daily from oily fish or supplements, while clinical trials targeting triglyceride reduction and major cardiovascular event prevention have used pharmacological doses of 2–4 g/day. The landmark REDUCE-IT trial demonstrated a 25% reduction in major adverse cardiovascular events using 4 g/day of pure EPA (icosapentaenoic acid) in high-risk statin-treated patients, suggesting higher doses are needed for therapeutic—rather than preventive—cardiovascular benefit. Always consult a physician before exceeding 3 g/day, particularly if using anticoagulant medications.
What is the difference between triglyceride form and ethyl ester fish oil?
Natural fish oil exists in triglyceride (TG) form, where EPA and DHA are bound to a glycerol backbone, while ethyl ester (EE) form is a semi-synthetic concentrate created by transesterification, replacing the glycerol with ethanol to increase EPA/DHA concentration per capsule. Re-esterified triglyceride (rTG) form—produced by reattaching concentrated EPA/DHA ethyl esters back onto glycerol—offers the highest bioavailability, approximately 70% greater than ethyl ester form in fasted conditions. For maximum absorption from any form, take fish oil capsules with a high-fat meal, which can increase ethyl ester bioavailability by up to 300%, effectively narrowing the gap between forms.
Can fish oil from sardines and anchovies contain harmful levels of mercury?
Small pelagic fish like sardines and anchovies sit low on the marine food chain and bioaccumulate significantly less mercury and persistent organic pollutants (PCBs, dioxins) than larger predatory fish such as tuna, swordfish, or shark. Commercially processed sardine and anchovy fish oil undergoes molecular distillation—a high-vacuum, high-temperature purification process—that reduces contaminants to levels well below established safety thresholds (e.g., <0.1 ppm mercury, <0.09 ng/g PCBs per IFOS standards). Third-party certified products (IFOS, NSF International, USP) provide batch-tested certificates of analysis confirming contaminant levels, making purified sardine/anchovy oil among the safest omega-3 supplement sources available.
Does fish oil interact with blood thinners like warfarin?
Omega-3 fatty acids at doses above approximately 2–3 g EPA+DHA per day exert antiplatelet effects by reducing thromboxane A2 synthesis and modestly prolonging bleeding time, which can theoretically potentiate the anticoagulant effect of warfarin, clopidogrel, aspirin, or newer anticoagulants (apixaban, rivaroxaban). Clinical evidence suggests the interaction is generally modest at standard supplemental doses (1–2 g/day) and rarely causes clinically significant bleeding, but INR monitoring is prudent when initiating or changing fish oil doses in patients on warfarin. Patients on anticoagulation therapy should inform their physician before starting fish oil supplementation and should discontinue approximately 7–10 days before elective surgery.
Is fish oil effective for reducing inflammation and joint pain?
Clinical trials in rheumatoid arthritis patients using 2.7–3 g/day of combined EPA+DHA for 12–24 weeks have shown statistically significant reductions in tender joint counts, morning stiffness duration, and NSAID requirement compared to placebo, with effect sizes in the small-to-moderate range (SMD approximately −0.3 to −0.5). The mechanism involves EPA and DHA competitively displacing arachidonic acid from membrane phospholipids, reducing production of pro-inflammatory prostaglandin E2 and leukotriene B4, while also generating anti-inflammatory and pro-resolving lipid mediators including resolvins and protectins that actively terminate inflammatory cascades. Benefits for osteoarthritis and general inflammatory conditions are less robustly established but are supported by a growing body of observational and interventional evidence, particularly at doses of 2–3 g/day maintained for at least 8–12 weeks.
What is the recommended dose of EPA and DHA fish oil for triglyceride reduction?
Clinical evidence shows that 2–4 grams per day of combined EPA and DHA can reduce serum triglycerides by 15–30% through mechanisms including reduced hepatic VLDL synthesis and enhanced lipoprotein lipase-mediated clearance. This dose range is recognized in FDA-approved prescription fish oil formulations and represents the most effective threshold for triglyceride-lowering benefits. Individual responses vary based on baseline triglyceride levels and overall diet, so consult a healthcare provider to determine your optimal dose.
Is fish oil from sardines and anchovies safer than other fish sources regarding contaminants?
Sardines and anchovies are among the safest fish sources for omega-3 supplementation because they are small, short-lived fish with minimal bioaccumulation of heavy metals like mercury compared to larger predatory fish. Their rapid reproduction cycle and lower trophic level mean less time for contaminant accumulation in their tissues. High-quality sardine and anchovy fish oils undergo molecular distillation and third-party testing to further reduce any residual contaminants.
Can fish oil EPA and DHA improve endothelial function and cardiovascular outcomes beyond triglyceride reduction?
Yes, EPA and DHA improve endothelial function by enhancing nitric oxide bioavailability, which promotes vasodilation and reduces platelet aggregation—mechanisms that work independently of triglyceride reduction to lower cardiovascular event risk. Clinical research demonstrates these benefits contribute to improved arterial flexibility, reduced blood pressure, and decreased thrombotic risk in regular users. These vascular improvements are particularly valuable for individuals with existing cardiovascular disease or multiple risk factors.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w omega-3-fatty-acids-dhaepa-fish-oil-from-sardine-and-anchovy curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
